The therapeutic effect and safety of the drugs for COVID-19: a systematic review and meta-analysis

Rong Qiu  
Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China

Jingwei Li (✉️ 13032869669@163.com)  
Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China

Yuxuan Xiao  
West China School/Hospital of Stomatology, Sichuan University, Chengdu, China.

Ziyi Gao  
West China Medical School/West China Hospital, Sichuan University, Chengdu, China.

Yihang Weng  
West China School/Hospital of Stomatology, Sichuan University, Chengdu, China.

Qiran Zhang  
West China Medical School/West China Hospital, Sichuan University, Chengdu, China.

Chengdi Wang  
Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China

Hanlin Gong  
Department of integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.

Weimin Li  
Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China

Systematic Review

Keywords: COVID-19, medicine, safety, efficiency, meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-89225/v1

License: ☇️  This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Coronavirus disease 2019 (COVID-19) has spread almost all regions of the world and caused great loss to the whole body of mankind. Thus, numerous clinical trials were conducted to find specific medicine for COVID-19 recently. However, it remains unanswered whether they are beneficial.

Objective: This study aimed to evaluate the efficiency and safety of the COVID-19 medicine.

Methods: Studies were determined through searching PubMed, Embase, Cochrane Library and Medline. The clinical trials of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement and rate of serious adverse events. The risk ratio (RR) was adopted for variables as effect magnitude with 95% confidence intervals (CI), and the random-effects model was adopted for analysis.

Results: A total of eleven RCTs and eleven Non-RCTs involving 12,796 patients were included in our study, whose intervening measures contained three major types of COVID-19 medicine, ACEI/ARB, antiviral medicine and chloroquine/hydroxychloroquine. Compared to control group, COVID-19 medicine has the obvious advantage in reducing discharge rate (RR, 1.18; 95% CI, 1.07-1.29, p<0.05) and clinical improvement rate (RR, 1.15; 95% CI, 1.05-1.26, p<0.05), no distinct effect on mortality (RR, 0.79; 95% CI, 0.53-1.17, p=0.24). In addition, the serious adverse events rate (RR, 0.74; 95% CI, 0.62-0.88, p<0.05) of COVID-19 medicine is lower than control group. Among different types of medicine, significant benefits in lowering the mortality seem to only occur in antiviral medicine.

Conclusion: The results indicated antiviral medicine was potential drug of first choice recommended for COVID-19 treatment. Chloroquine/hydroxychloroquine therapy was not recommended for COVID-19 patients. Additionally, the ACEI/ARB could be adopted for COVID-19 treatment when combined with standard treatment.

Introduction

In December 2019, an outbreak of novel pneumonia swept through Wuhan, Hubei province, which was proved to be caused by a novel kind of coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) later\(^1,2\). Due to its high infectivity, the novel pneumonia quickly spread around the world and was named coronavirus disease 2019 (COVID-19) by WHO\(^3\). Up to Sept. 2nd, COVID-19 has hit more than 200 Countries and regions, and the amount of confirmed COVID-19 patients has reached 25,602,665\(^4\), resulting in great loss of material resources, financial and manpower.

For better battling against the disease, scientific researchers and medical workers around the world have been searching for appropriate methods to control the outbreak, such as isolation of patients, wearing N95, KN95 masks and timely treatment of patients\(^5,6\). Because SARS-CoV-2 is a novel virus, and its properties are still unknown, treatment is one of the major difficulties among them. Therapeutic options for the COVID-19 are mainly divided into etiological treatment and symptomatic treatment. Symptomatic
treatment means treating complications of diseases. For example, fever and hypoxia are common complications of COVID-19 patients\textsuperscript{7,8}, thus symptomatic treatment for them are oxygen inhalation and quelling fever. Etiological treatment for COVID-19 is using antiviral medicine or products of SARS-CoV-2 to suppress propagation of the virus\textsuperscript{9}. Nevertheless, there remain lacks specific medicine for COVID-19. The COVID-19 medicine can be generally divided into Angiotensin-converting enzyme inhibitors (ACEI) / angiotensin-receptor blockers (ARB), antiviral medicine and chloroquine/hydroxychloroquine. ACEI/ARB is frequently used for hypertension therapy and hypothesized to suppress the combination between SARS-CoV-2 and its receptors, which probably cure the COVID-19. However, its safety is uncertain\textsuperscript{10}. The common antiviral medicine for COVID-19 are remdesivir, lopinavir/ritonavir and so on. In vitro study, they exerted their antiviral effect at low concentration and with the high selectivity index\textsuperscript{11}, demonstrating their potential for treatment of COVID-19. Therefore, in order to find appropriate etiological treatment as quickly as possible, hundreds of clinical trials have been started to evaluate the efficiency and safety of these medicine or products. Nevertheless, the current results of trials are controversial. The first report of clinical trial results showed that lopinavir/ritonavir failed to improve the clinical symptoms significantly\textsuperscript{12}. On the contrary, the clinical data of remdesivir showed that remdesivir prominently shortened the time of clinical improvement and reduced the mortality of severe COVID-19 patients\textsuperscript{13}. Furthermore, clinical data of chloroquine indicated it may not be the efficient medicine similarly\textsuperscript{14}. Even worse, the mortality of the patients was higher after using chloroquine\textsuperscript{14}. However, study of Gao, J et al. showed an apparent efficacy in treatment of COVID-19 patients\textsuperscript{15}.

Due to the inconsistencies of clinical results, scientific methods should be adopted to comprehensively evaluate the efficacy and safety of existing medicine and products of COVID-19. Therefore, this study summarized the published clinical data of them and evaluated their safety efficiency. Moreover, we also compared efficiency and safety indicators among different kinds of medicine and products of COVID-19, hoping to provide evidence for clinical treatment.

**Materials And Methods**

This study is a meta-analysis and systematic review of clinical trials including randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) which focus on the efficiency or safety of the COVID-19 medicine. In addition, all processes of this study are based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)\textsuperscript{16}.

**Research strategy**

Keywords associated with the clinical trial of COVID-19 including COVID-19 (coronavirus disease 2019 or COVID-19 or severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2) and trials of treatment (trial or clinical trial or treatment or therapy or medicine or ARB/ACEI or HCQ) were adopted to search in PubMed, Embase, Cochrane Library and Medline from January 2020 to September 2020. The types of
publication and language are not restricted, except for unpublished trials. Moreover, the complete data of studies were enrolled for judgement of repeated trials.

**Inclusion criteria and selection of the studies**

Inclusion and exclusion criteria were predetermined. The eligible studies were included according to the following criteria: Patients: confirmed COVID-19 cases (Age ≥ 18); Intervention: patients in experimental group were received medicine therapy of COVID-19, with the addition of basic treatment as control group; Control group: basic treatments or placebo; Outcomes: efficiency (e.g. mortality, discharge rate, clinical improvement rate), Safety (e.g. rate of adverse events); Study types: clinical trials were adopted. Studies which met the following criteria were excluded: data is lacking or incomplete; duplicated studies; studies published in form of reviews, meta-analysis, case reports, letters, editorials or commentaries.

The title and abstract were firstly screened by two reviewers independently. Then, for further screening the articles that were difficult to distinguish through title/abstract, the full texts were retrieved for evaluation. All the disagreements were solved via discussion between two reviewers or opinions of the third party.

**Data extraction and quality evaluation**

First author, year of publication, number of patients, therapeutic method and type of study were extracted in every study. Furthermore, the extractable efficiency indicators (mortality, discharge rate, improvement rate) or safety indicator (serious adverse events) were obtained in trials.

The quality of RCTs included was evaluated via Cochrane Handbook\(^{17}\), which is composed of six items: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, no selective outcome reporting and other sources of bias. Items identified as "low risk" are considered appropriate. Total score of the study is 6. The higher the score, the better the quality of the study.

The Newcastle-Ottawa Scale (NOS) assesses the quality of Non-RCTs with eight questions: case definition adequate; representativeness of the Cases; selection of controls; definition of controls; comparability of cases and controls; ascertainment of exposure; use the same method to determine case and control exposure factors; non-response rate. The range of score is 0 to 9. Also, the higher the score, the better the quality of the study.

**Statistical analysis**

Review Manager (version 5.3; Nordic Cochrane Center, Cochrane Collaboration, Copenhagen, Denmark) was adopted to conduct statistical analysis. For efficiency and safety outcomes, the risk ratio (RR) was adopted, which were calculated through the 95% confidence intervals (CI), with the employ of random effect model in consideration of the heterogeneity of COVID-19 medicine\(^{18}\). Statistical heterogeneity was calculated through \(I^2\) statistic, and value of > 50% was considered as high heterogeneity\(^{19,20}\). Publication bias was detected by funnel plots if enough articles (more than 10) were adopted for an outcome.
Moreover, sensitivity analyses and subgroup analyses would be performed to explain the sources of heterogeneity if the trials were enough. P<0.05 is thought to be statistically significant.

**Result**

**Literature research**

The screening process was shown in figure 1 and 3860 studies were identified according to the research strategy initially. In total, 22 studies containing 12795 patients were adopted in our study and all of them were published in English\textsuperscript{10,12,21-40}. Among trails included, half of them were RCTs, and the other were Non-RCTs. Furthermore, 8 studies investigated potential efficiency and safety of ACEI /ARB for coivd-19; 9 of them aimed at the antiviral medicine of COVID-19 with remaining 5 studies caring about hydroxychloroquine and chloroquine.

**Characteristics of the studies**

All trails (Table 1) were carried out in 2020, which included 11 Non-RCTs and 11 RCTs. Intervention groups of the trails received COVID-19 medicine (antiviral treatment, ACEI /ARB, hydroxychloroquine/chloroquine) plus standard treatment including oxygen inhalation, reducing the fever and so on. By contrast, the treatment received by control group were standard treatment with or without simple antiviral medicine. Among the studies, 5290 patients were allocated to COVID-19 medicine groups while 7505 patients in control groups. As for the patients received COVID-19 medicine, 2101 patients (39.7%) participated in the trials of ACEI/ARB compared with 1831 patients (34.6%) and 1358 patients (25.8%) enrolled in the trails of antiviral medicine or hydroxychloroquine/chloroquine. Respectively, 8 studies were conducted for ACEI /ARB for covid-19, 9 for antiviral medicine of COVID-19, 5 for hydroxychloroquine or chloroquine.

| Table 1. Characteristic of trials included |
|-------------------------------------------|
| All trails (Table 1) were carried out in 2020, which included 11 Non-RCTs and 11 RCTs. Intervention groups of the trails received COVID-19 medicine (antiviral treatment, ACEI /ARB, hydroxychloroquine/chloroquine) plus standard treatment including oxygen inhalation, reducing the fever and so on. By contrast, the treatment received by control group were standard treatment with or without simple antiviral medicine. Among the studies, 5290 patients were allocated to COVID-19 medicine groups while 7505 patients in control groups. As for the patients received COVID-19 medicine, 2101 patients (39.7%) participated in the trials of ACEI/ARB compared with 1831 patients (34.6%) and 1358 patients (25.8%) enrolled in the trails of antiviral medicine or hydroxychloroquine/chloroquine. Respectively, 8 studies were conducted for ACEI /ARB for covid-19, 9 for antiviral medicine of COVID-19, 5 for hydroxychloroquine or chloroquine. |
| First author | Type of study | Location | No. of patients (male) | Treatment | Control |
|--------------|--------------|----------|-----------------------|-----------|---------|
| Gao C        | Non-RCT      | China    | 58                    | Interventions (RAAS Inhibitor) + SOC | Control: No Antihypertension + SOC Non-ARB/ACEI + SOC |
| Yang G       | Non-RCT      | China    | 66                    | Interventions (RAAS Inhibitor) + SOC | Control: No Antihypertension + SOC Non-ARB/ACEI + SOC |
| Hu J         | Non-RCT      | China    | /                     | ARB/ACEI + SOC | Control: Non-ARB/ACEI + SOC |
| Fosbol E.L.  | Non-RCT      | Denmark  | /                     | ARB/ACEI + SOC | Control: Non-ARB/ACEI + SOC |
| Zhang P      | Non-RCT      | China    | 64                    | ARB/ACEI + SOC | Control: Non-ARB/ACEI + SOC |
| Meng J       | Non-RCT      | China    | 64.5                  | ARB/ACEI + SOC | Control: Non-ARB/ACEI + SOC |
| Li J         | Non-RCT      | China    | 66.0                  | ARB/ACEI + SOC | Control: Non-ARB/ACEI + SOC |
| Felice C     | Non-RCT      | Italy    | 73                    | ARB/ACEI + SOC | Control: Non-RAAS Inhibitor + SOC |
| Davoudi-Monfared E | RCT   | Iran     | /                     | IFN β-1a + HCQ + Lopinavir-Ritonavir/Atazanavir-Ritonavir | Control: HCQ + Lopinavir-Ritonavir/Atazanavir-Ritonavir |
| Hung I.F.    | RCT          | China    | 51.3                  | Lopinavir-Ritonavir + Ribavirin + Interferon beta-1b + SOC | Control: Lopinavir-Ritonavir + SOC |
| Cao B        | RCT          | China    | 58.0                  | Lopinavir-Ritonavir + SOC | Control: SOC |
| Li Y         | RCT          | China    | 49.4                  | Lopinavir-Ritonavir + SOC /Arbidol +SOC | Control: SOC |
| Wang Y       | RCT          | China    | 65.3                  | Remdesivir + SOC | Control: Placebo + SOC |
| Beigel J.H.  | RCT          | U.S., Korea, etc. | 58.9 | Remdesivir + SOC | Control: Placebo + SOC |
| Olender S.A. | RCT          | U.S., Korea, etc. | / 312 | Remdesivir + SOC | Control: SOC |
| Spinner C.D. | RCT          | U.S., U.K, etc. | / 384(232) | Remdesivir + SOC | Control: SOC |
| Ivashchenko A.A. | RCT    | Russia   | / 40                  | Avifavir + SOC | Control: SOC |
| Boulware D.R. | RCT        | U.S., Canada | 40.5 | Hydroxychloroquine + SOC | Control: Placebo + SOC |
| Geleris J    | Non-RCT      | U.S.     | / 811(474)            | Hydroxychloroquine + SOC | Control: No Hydroxychloroquine + SOC |
| Gautret P    | Non-RCT      | France   | 45.1                  | Hydroxychloroquine + SOC | Control: No Hydroxychloroquine + SOC |
| Paccoud O    | Non-RCT      | France   | 65.5                  | Hydroxychloroquine + SOC | Control: SOC |
| Tang W       | RCT          | China    | 46.1                  | Hydroxychloroquine + SOC | Control: SOC |

Abbreviations: RAAS, renin-angiotensin-aldosterone system; SOC, standard of care; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; IFN, interferon; HCQ, hydroxychloroquine

Quality evaluation of studies
The quality evaluation of the 11 RCTs included was shown in Table S1. All of them showed sequence generation in detail and no selective outcome reporting, but only 3 studies of them described the method used for allocation concealment together with blinding of participants, personnel and outcome assessors. Additionally, only 2 studies didn’t describe how to deal with incomplete outcome data. However, only 4 articles showed high risk in other sources of bias. In summary, the qualities of RCTs selected varied from moderate to high.

Half of studies (11) included were Non-RCTs and assessed for the quality by NOS. The evaluation was demonstrated in Table S2. The maximum quality score in NOS is 9, and the range of score of included Non-RCTs is 4 to 7, with a median of 6. Among the 11 studies, all of them reported the adequate definition of case, representativeness of the cases, definition of controls and non-response rate. Regrettably, 2 studies omitted the comparability of cases and controls and less than half of studies (5) used the same method to determine case and control exposure factors. Overall, the Non-RCTs included showed a high quality.

**Primary analysis**

**Efficiency**

In general, seventeen studies involving treatments of antiviral medicine, ACEI/ARB and hydroxychloroquine/chloroquine were included for mortality evaluation, and there was no obvious in mortality difference between COVID-19 medicine groups and control groups (RR, 0.79; 95% confidence interval [CI], 0.53-1.17, p=0.24) (Figure 2). In addition, compared with control groups, COVID-19 medicine resulted in significant increases in discharge rate (RR, 1.18; 95% confidence interval [CI], 1.07-1.29, p<0.05). (Figure 3) The endpoint of clinical improvement rate only existed in the treatment of antiviral medicine, which indicated the clinical improvement rate of antiviral medicine was higher than control group, with a significantly statistical difference (RR, 1.15; 95% confidence interval [CI], 1.05-1.26, p<0.05) (Figure 4).

**Safety**

In terms of safety of new therapies, reduction in occurrence of serious adverse events was achieved in experiment groups which made use of ACEI/ARB, antiviral medicine and hydroxychloroquine/chloroquine in comparison with the standard treatment (RR, 0.74; 95% confidence interval [CI], 0.62-0.88, p<0.05) (Figure 5).

**Subgroup analysis**

In accordance with types of used drugs, studies included were divided into subgroup of ACEI/ARB, subgroup of antiviral medicine, subgroup of hydroxychloroquine/chloroquine respectively, and differences were analyzed and displayed in Figure 6. Unlike the result that
overall drug mortality had no statistical difference, a remarkable reduction existed in mortality in subgroups of antiviral medicine (RR, 0.66; 95% confidence interval [CI], 0.52-0.82, p<0.05). Conversely, evidence was insufficient to support any improvement in mortality for subgroups of ACEI/ARB (RR, 0.75; 95% confidence interval [CI], 0.34-1.63, p=0.47). Similarly, there was no obvious statistical difference within mortality reduction in subgroups of the hydroxychloroquine/chloroquine compared with control groups (RR, 1.23; 95% confidence interval [CI], 0.51-2.96, p=0.64).

**Bias of publication**

Funnel chart was used for the assessment of publication bias, and it revealed there was no obvious bias existed in studies included.

**Discussion**

This analysis included 22 studies with high quality, which involved 12796 patients and revealed that COVID-19 medicine had the better therapeutic effect in discharge rate, clinical improvement rate and safety end point than standard of care, but the significant decrease in mortality didn’t appear among them. Furthermore, compared to other medicine, antiviral medicine led to obvious reduction in mortality, indicating this category of medicine owned the greatest curative effect among all COVID-19 medicine and had the potential to be specific medicine of COVID-19.

The current researches have showed different outcomes among COVID-19 medicine. For ACEI/ARB, Gao, C and colleague conducted the earliest meta-analysis combined with their research data to validate its therapeutic effect and found that ACEI/ARB could significantly reduce the mortality of COVID-19 patients\(^27\). However, this study revealed that ACEI/ARB hadn’t significant effect in reducing mortality, demonstrating ACEI/ARB may not be the ideal medicine for COVID-19 treatment. After re-examining studies about ACEI/ARB included, data of all studies indicated ACEI/ARB had influence in mortality decrease, except for Fosbol, E. L, et al. Then, we looked through the full text and discovered that the patients in experimental group were more likely to have basic diseases compared to control group, which perhaps caused the higher mortality\(^10\). After removing this study, analysis result showed a significant decrease in mortality of COVID-19 patients. (RR, 0.61; 95% confidence interval [CI], 0.45-0.82, p<0.05) Therefore, more trials should be conducted to further evaluate the therapeutic effect of ACEI/ARB. For antiviral medicine, although quite a few controversies existed, none of study comprehensively analyzed their safety and curative effect. Therefore, we did the subgroup analysis to confirm the safety and curative effect among almost all end points. when it comes to chloroquine/hydroxychloroquine, the significant difference in therapeutic efficiency wasn't seen between experimental group and control group either, which is consistent with previously published studies\(^41\). Moreover, in spite of the significant clinical improvement in antiviral medicine, the heterogeneity still needs to be noticed. \(I^2\) value of 61% indicated the heterogeneity existed, so we removed the studies one by one and found that after removing the study of Olender, S. A, et al\(^32\), the \(I^2\) value became 0%, demonstrating this study might be the source of
heterogeneity. Immediately, we made the comparison among studies involved in analysis of clinical improvement rate and revealed that all studies are RCTs except for Olender, S. A, et al, reflecting unprecise control conditions and lack of blind method settings played the important role in heterogeneity.

It’s worth noting that antiviral therapy appeared greater therapeutic effect compared with the ACEI/ARB and chloroquine/hydroxychloroquine therapy. In theory, ACEI/ARB inhibit the combination of angiotensin-converting enzyme 2 (ACE2), binding site of SARS-CoV-2, and SARS-CoV-2 to benefit COVID-19 patients\(^42\). However, it may also promote the expression of ACE2 and attenuate therapeutic effect. Besides, although chloroquine/hydroxychloroquine had considerable antiviral effect in vitro, its antiviral mechanism is still unknown. In contrast, antiviral medicine could block the proliferation of SARS-CoV-2 through different ways\(^43\), which is the obvious target treatment for SARS-CoV-2 theoretically. That may explain the better therapeutic effect of antiviral therapy. Nonetheless, their underlying mechanisms remain unclear, so more researches are needed to validate our hypothesis.

In terms of safety, there is still much controversy. The current study showed that the chloroquine/hydroxychloroquine has already on the market, but the clinical trials of chloroquine/hydroxychloroquine have indicated that the high doses use of it would increase the mortality as well as prolonged QT interval of COVID-19 patients’ electrocardiogram\(^14,44,45\), which is dangerous for patients. Furthermore, compassionate use of remdesivir showed that nearly 60% COVID-19 patients had side effects\(^13\). Inversely, some other studies indicated COVID-19 medicine would not increase safety risk\(^12,29,31\). Nevertheless, this study first discussed that treating with COVID-19 medicine not only didn’t increase safety risks, but also decreased the rate of the serious adverse events of COVID-19 patients. The result above demonstrated that COVID-19 drug therapy was even the safer treatment than standard care. Thus, standard treatment combined with COVID-19 medicine should be recommended for COVID-19 patients’ treatment.

**Implications of the study**

Our study has clinical implication for guiding rational drug use. On the one hand, we recommend the appropriate medicine for COVID-19 patients. Nowadays, due to the absence of effective medicine for COVID-19 patients, treatments for them are mainly symptomatic treatments\(^46\). In this study, antiviral medicine including remdesivir, lopinavir-ritonavir and so on was found to have potential to reduce the mortality and improve the clinical symptom, with little adverse events, thus we advise that antiviral medicine should be adopted for priority use. On the other hand, ACEI/ARB and chloroquine/hydroxychloroquine therapy do not seem to be the ideal treatments for COVID-19 therapy. In early February, chloroquine/hydroxychloroquine was reported to have apparent antiviral effect on SARS-CoV-2\(^11\), and then it was recommend for treatment of COVID-19 patients soon. As the clinical trials continued, chloroquine/hydroxychloroquine didn't exert the clinical effect as people expected\(^36,37\), thus it was gradually not recommended for use alone. We comprehensively analyzed data of the trials which used chloroquine/hydroxychloroquine and confirmed it did not reduce the mortality significantly as compared with standard care. Furthermore, although these drugs seem to have little serious adverse
events, the side effects of prolonged QT interval and ventricular tachycardia should be noticed\textsuperscript{44,45}. For those with inherent cardiovascular disease, the side effects above could significantly increase security risks. Thus, we don’t recommend the treatment with chloroquine/hydroxychloroquine for COVID-19 patients, especially for those with cardiovascular disease. With regard to ACEI/ARB, the study showed that it might not have the therapeutic effect in treating COVID-19. However, in terms that the patients in experimental group in study of Fosbol, E. L, et al. tended to have basic diseases compared to control group, confirming whether ACEI/ARB could reduce the mortality of COVID-19 patients is difficult. With the addition of safety of ACEI/ARB treatment, we suspected combination of ACEI/ARB and standard treatment play the potential role in curing COVID-19. Nonetheless, using the ACEI/ARB alone is not recommended. Thus, in the study, we draw a conclusion that antiviral medicine was probably the ideal specific medicine of COVID-19 due to its potential of mortality decrease and clinical symptoms improvement. Chloroquine/hydroxychloroquine was not recommended for COVID-19 patients because of its safety risk and little therapeutic effect. As for ACEI/ARB, its curative effect is uncertain, thus we think combination use of ACEI/ARB and standard treatment is worthy of adopting for COVID-19 treatment. Because their therapeutic mechanisms for COVID-19 are remain unclear, and the sample size for each medicine is insufficient, more studies are needed for further confirming their efficiency and safety.

**Strengths and weaknesses of the study**

There exist several strengths in our study. First, we are the first to evaluate the therapeutic effect and safety for the most comprehensive categories of COVID-19 medicine. The therapeutic trials of most common kinds of COVID-19 medicine, ACEI/ARB, antiviral medicine and chloroquine/hydroxychloroquine, were all included in our study. Our findings showed the significant curative effect on clinical improvement was confirmed in COVID-19 medicine compared to standard treatment. Currently, lack of comparison between different categories of medicine makes it difficult for clinicians to adopt appropriate medicine to treat COVID-19 patients, thus, we are also the first to do the indirect subgroup analysis among these categories of medicine and found that antiviral medicine had the advantage in reducing mortality over ACEI/ARB and chloroquine/hydroxychloroquine with significant difference statistically. Furthermore, the serious adverse events of COVID-19 medicine were generally lower than standard treatment, demonstrating the better safety of COVID-19 medicine. Second, the high quality of the data is another remarkable strength in this study. With the data obtained in 17 trials, we gathered more than 1,2000 patients for quantitative analysis of mortality, which is the largest scale of COVID-19 patients for assessing the mortality of COVID-19 medicine up to now. Such large-scale number of patients included in our study ensured the statistical accuracy. Third, we recommended the antiviral medicine as the priority drug among COVID-19 medicine and did not support the chloroquine/hydroxychloroquine therapy, especially for patients with cardiovascular diseases. Fourth, we comprehensively look through the full text both before and after the data analysis and hypothesized that ACEI/ARB was potential specific medicines for COVID-19 patients. Although the subgroup analysis of ACEI/ARB therapy appeared that it was not associated with the mortality decrease COVID-19 patients initially, we found that one of the studies involved existed the obviously higher basic disease rate in experimental group over control group.
After removing it, the result showed a reduction of mortality in ACEI/ARB compared to standard care with statistically significant P value and little heterogeneity, which is consistent with previous study\textsuperscript{47}.

Despite the strengths above, the limitations still exist in this study. One is that the efficiency indicators aren’t elaborate enough. Though we have comprehensively selected the indicators contain clinical improvement, discharge and mortality to evaluate the efficiency of COVID-19 medicine, the more precise indicators such as levels of cytokines, temperature variation and creatinine levels are impossible to obtain among most studies. Therefore, we had to assess the efficiency through these simple indicators. Another limitation is that classification of COVID-19 medicine exists problem. For instance, there are many kinds of antiviral medicine, and they may have controversial therapeutic effects. However, the quantity of eligible studies for each medicine is insufficient for analysis, and the weak heterogeneity among intragroup medicine indicated our correctness.

**Conclusion**

In summary, this study indicated that COVID-19 medicine had an apparent effect on mortality decrease, discharge rate and clinical improvement increase of COVID-19 patients, with reduction of the rate of serious adverse events. Furthermore, among different kinds of COVID-19 medicine, antiviral medicine had better effect on reducing mortality, thus it had the potential to be priority drug for treatment. However, due to the insufficient quantity of trials, efficiency and safety of every single medicine cannot be evaluated in detail.

**Declarations**

**Conflict of interests:** Authors declared they had no conflict of interest.

**Ethics approval:** Not required.

**Availability of data and material:** The data gathered and/or analyzed in this study can be obtained from corresponding authors upon reasonable request.

**Author Contributions:** W. L and H. G designed this study; J. L, Y. X and Q. Z established searching strategy and collected the data; J. L and R. Q performed statistical analyses and wrote the manuscript; C. W, Z. G and Y. W assisted in the data analyses and manuscript writing. All authors looked through and agreed to the final manuscript.

**References**

1 Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *The New England journal of medicine* **382**, 1199-1207, doi:10.1056/NEJMoa2001316 (2020).
2 Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The New England journal of medicine* **382**, 727-733, doi:10.1056/NEJMoa2001017 (2020).

3 McMichael, T. M. et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. *The New England journal of medicine* **382**, 2005-2011, doi:10.1056/NEJMoa2005412 (2020).

4 WHO. *WHO Coronavirus Disease (COVID-19) Dashboard*, <https://covid19.who.int/> (2020).

5 Pompeii, L. A. et al. Training and Fit Testing of Health Care Personnel for Reusable Elastomeric Half-Mask Respirators Compared With Disposable N95 Respirators. *Jama* **323**, 1849-1852, doi:10.1001/jama.2020.4806 (2020).

6 Lan, L. et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. *Jama* **323**, 1502-1503, doi:10.1001/jama.2020.2783 (2020).

7 Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine* **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).

8 Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)* **395**, 507-513, doi:10.1016/S0140-6736(20)30211-7 (2020).

9 Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science* **368**, 779-782, doi:10.1126/science.abb7498 (2020).

10 Fosbol, E. L. et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. *JAMA* **324**, 168-177, doi:10.1001/jama.2020.11301 (2020).

11 Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell research* **30**, 269-271, doi:10.1038/s41422-020-0282-0 (2020).

12 Cao, B. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *The New England journal of medicine* **382**, 1787-1799, doi:10.1056/NEJMoa2001282 (2020).

13 Grein, J. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *The New England journal of medicine* **382**, 2327-2336, doi:10.1056/NEJMoa2007016 (2020).

14 Borba, M. G. S. et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA network open* **3**, e208857, doi:10.1001/jamanetworkopen.2020.8857 (2020).
15 Gao, J., Tian, Z. & Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in
treatment of COVID-19 associated pneumonia in clinical studies. *Bioscience trends* **14**, 72-73,
doi:10.5582/bst.2020.01047 (2020).

16 Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* **151**, 264-269, W264,
doi:10.7326/0003-4819-151-4-200908180-00135 (2009).

17 Higgins, J. P. *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised
trials. *BMJ (Clinical research ed.)* **343**, d5928, doi:10.1136/bmj.d5928 (2011).

18 DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control Clin Trials* **7**, 177-188,
doi:10.1016/0197-2456(86)90046-2 (1986).

19 Higgins, J., Thompson, S., Deeks, J. & Altman, D. Statistical heterogeneity in systematic reviews of
clinical trials: a critical appraisal of guidelines and practice. *J Health Serv Res Policy* **7**, 51-61,
doi:10.1258/1355819021927674 (2002).

20 Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-
analyses. *BMJ (Clinical research ed.)* **327**, 557-560, doi:10.1136/bmj.327.7414.557 (2003).

21 Felice, C. *et al.* Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from
an Italian cohort of 133 hypertensives. *American journal of hypertension*, doi:10.1093/ajh/hpaa096
(2020).

22 Meng, J. *et al.* Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19
patients with hypertension. *Emerging microbes & infections* **9**, 757-760,
doi:10.1080/22221751.2020.1746200 (2020).

23 Yang, G. *et al.* Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting
Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With
COVID-19 and Hypertension: A Single-Center Retrospective Study. *Hypertension (Dallas, Tex. : 1979)*
**76**, 51-58, doi:10.1161/HYPERTENSIONAHA.120.15143 (2020).

24 Hu, J. *et al.* COVID-19 patients with hypertension have more severity condition, and ACEI/ARB
 treatment have no influence on the clinical severity and outcome. *The Journal of infection*,
doi:10.1016/j.jinf.2020.05.056 (2020).

25 Li, J., Wang, X., Chen, J., Zhang, H. & Deng, A. Association of Renin-Angiotensin System Inhibitors
With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019
(COVID-19) Infection in Wuhan, China. *JAMA Cardiol* **5**, 825-830, doi:10.1001/jamacardio.2020.1624
(2020).
26 Zhang, P. et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circ Res* **126**, 1671-1681, doi:10.1161/CIRCRESAHA.120.317134 (2020).

27 Gao, C. et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. *European heart journal* **41**, 2058-2066, doi:10.1093/eurheartj/ehaa433 (2020).

28 Davoudi-Monfared, E. et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon beta-1a in Treatment of Severe COVID-19. *Antimicrob Agents Chemother* **64**, doi:10.1128/AAC.01061-20 (2020).

29 Hung, I. F. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet (London, England)* **395**, 1695-1704, doi:10.1016/S0140-6736(20)31042-4 (2020).

30 Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet (London, England)* **395**, 1569-1578, doi:10.1016/S0140-6736(20)31022-9 (2020).

31 Beigel, J. H. et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *The New England journal of medicine*, doi:10.1056/NEJMoa2007764 (2020).

32 Olender, S. A. et al. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. *Clin Infect Dis*, doi:10.1093/cid/ciaa1041 (2020).

33 Li, Y. et al. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. *Med (N Y)*, doi:10.1016/j.medj.2020.04.001 (2020).

34 Spinner, C. D. et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA* **324**, 1048-1057, doi:10.1001/jama.2020.16349 (2020).

35 Ivashchenko, A. A. et al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. *Clin Infect Dis*, doi:10.1093/cid/ciaa1176 (2020).

36 Geleris, J. et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *The New England journal of medicine* **382**, 2411-2418, doi:10.1056/NEJMoa2012410 (2020).

37 Cavalcanti, A. B. et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *The New England journal of medicine*, doi:10.1056/NEJMoa2019014 (2020).
38 Tang, W. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ (Clinical research ed.)* **369**, m1849, doi:10.1136/bmj.m1849 (2020).

39 Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International journal of antimicrobial agents* **56**, 105949, doi:10.1016/j.ijantimicag.2020.105949 (2020).

40 Paccoud, O. et al. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital. *Clin Infect Dis*, doi:10.1093/cid/ciaa791 (2020).

41 Elavarasi, A. et al. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. *J Gen Intern Med*, doi:10.1007/s11606-020-06146-w (2020).

42 Gurwitz, D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. *Drug Dev Res* **81**, 537-540, doi:10.1002/ddr.21656 (2020).

43 Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**, 281-292 e286, doi:10.1016/j.cell.2020.02.058 (2020).

44 Chorin, E. et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. *Nat Med* **26**, 808-809, doi:10.1038/s41591-020-0888-2 (2020).

45 Chorin, E. et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. *Heart rhythm* **17**, 1425-1433, doi:10.1016/j.hrthm.2020.05.014 (2020).

46 Zhang, J. et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. *The Lancet. Respiratory medicine* **8**, e11-e12, doi:10.1016/S2213-2600(20)30071-0 (2020).

47 Zhang, X., Yu, J., Pan, L. Y. & Jiang, H. Y. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. *Pharmacological research* **158**, 104927, doi:10.1016/j.phrs.2020.104927 (2020).